The Intraduct Environment: A Novel Approach to Risk Assessment of Women With a Family History of Breast Cancer
gene expression analysis
+ protein expression analysis
+ cytology specimen collection procedure
Breast Diseases+3
+ Neoplasms
+ Neoplasms by Site
Screening Study
Summary
Study start date: November 1, 2003
Actual date on which the first participant was enrolled.OBJECTIVES: Primary Determine the incidence of mild or severe cellular atypia in nipple aspirate fluid of healthy women at moderate to high risk of developing breast cancer, defined by family history or prior atypical biopsy. Secondary Correlate cellular atypia with breast cancer, biochemical tumor markers, growth factors, and genetic and protein markers in these participants. Determine cancer risk and incidence utilizing these methods of screening in these participants. Observe the natural history of atypia in these participants over a total of 10 years. Determine whether these techniques may serve as supplementary tools in future screening of these participants. OUTLINE: Participants under 50 years of age undergo nipple aspiration every twelve months for 3 years. Participants over 50 years of age undergo nipple aspiration every 18 months for 4.5 years. Participants with significant cellular atypia in nipple aspirate fluid undergo ductal lavage and endoscopy. Participants are followed annually for a total of 10 years. PROJECTED ACCRUAL: A total of 1,000 participants will be accrued for this study within approximately 4 years.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.1000 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Screening Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Female
Biological sex of participants that are eligible to enroll.From 18 to 64 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
DISEASE CHARACTERISTICS: Significant family history or prior atypical biopsy indicative of a moderate or high risk of developing breast cancer No concurrent inflammatory breast cancer Hormone receptor status: Not specified PATIENT CHARACTERISTICS: Age 18 to 64 Sex Female Menopausal Status Premenopausal or postmenopausal Performance status Not specified Life expectancy Not specified Hematopoietic Not specified Hepatic Not specified Renal Not specified Other No prior allergy to EMLA cream or lidocaine No severe illness that would preclude study participation No mental illness or handicap that would preclude study compliance No concurrent active infection or inflammation in the breast being studied Not unconscious Not pregnant No nursing within the past 12 months PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy Not specified Endocrine therapy Not specified Radiotherapy Not specified Surgery No prior subareolar surgery (e.g., microdochectomy or major duct excision) that may disrupt the ductal systems within 2 cm of the nipple No prior breast implantation on proposed lavage side
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location